ASCO 2021: Updates in Myeloproliferative Neoplasms

home / publications / supplements / asco-2021-updates-in-myeloproliferative-neoplasms

This publication covers a multitude of presentations in myeloproliferative neoplasms that were presented and discussed during the 2021 ASCO Annual Meeting.

Jean-Jacques Kiladjian, MD, PhD, a professor of clinical pharmacologist at Paris Diderot University and a consultant hematologist and head of the Clinical Investigation Center at the Saint-Louis Hospital in Paris, France

Transfusion Independence With Momelotinib Confers Benefit Regardless of Baseline Factors in Myelofibrosis

Jessica Hergert
June 18th 2021
Article

Achieving transfusion independence after 24 weeks of treatment with momelotinib is associated with clinical benefit in patients with myelofibrosis irrespective of the degree of anemia, platelet count, or transfusion status at baseline.

Ruben A. Mesa, MD

Symptom Improvement Appears Similar With Momelotinib Vs Ruxolitinib in Myelofibrosis

Jessica Hergert
June 17th 2021
Article

Momelotinib can provide clinically relevant and comparable improvement in overall symptom burden and individual symptom items compared with ruxolitinib in patients with intermediate- and high-risk JAK inhibitor–naïve myelofibrosis.

Ruben A. Mesa, MD

Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis

Caroline Seymour
June 10th 2021
Article

Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.

Jan Philipp Bewersdorf, MD

Allo-Transplant Recommended for Eligible Patients With Myelofibrosis

Jessica Hergert
June 10th 2021
Article

Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.